SPRUCE BIOSCIENCES, INC. - 8-K Filing
Spruce Biosciences reported $54.1 million in cash and cash equivalents as of March 31, 2026, with gross proceeds from a recent public offering adding approximately $69.0 million before expenses. The company also announced long-term clinical data for TA-ERT at the WORLDSymposium™ showing durable reductions in heparan sulfate and cognitive stabilization in MPS IIIB patients. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $SPRB